Cargando…

Subgroup Analysis Stratified by Baseline Pancreatic β-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes

INTRODUCTION: This analysis investigated the relationship between baseline fasting pancreatic β-cell function and efficacy in Japanese patients with type 2 diabetes (T2D) treated with once-weekly dulaglutide 0.75 mg (dulaglutide) or once-daily liraglutide 0.9 mg (liraglutide) for up to 52 weeks. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iwamoto, Noriyuki, Matsui, Akiko, Kazama, Hirotaka, Oura, Tomonori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801232/ https://www.ncbi.nlm.nih.gov/pubmed/29264713 http://dx.doi.org/10.1007/s13300-017-0346-4

Ejemplares similares

The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes
por: Inagaki, Nobuya, et al.
Publicado: (2016)

Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen
por: Onishi, Yukiko, et al.
Publicado: (2020)

Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type 2 Diabetes: Exploratory Evaluation of the SURPASS J-mono Trial
por: Ishii, Hitoshi, et al.
Publicado: (2023)

Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11
por: Frias, Juan P., et al.
Publicado: (2021)

Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme
por: Mathieu, Chantal, et al.
Publicado: (2018)

Change in pharmacodynamic variables following once‐weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J‐mono substudy)
por: Yabe, Daisuke, et al.
Publicado: (2022)

Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies
por: Suzuki, Shuichi, et al.
Publicado: (2017)

Effect of Once-Weekly Dulaglutide on Glucose Levels in Japanese Patients with Type 2 Diabetes: Findings from a Phase 4, Randomized Controlled Trial
por: Inoue, Megumi, et al.
Publicado: (2019)

Dulaglutide 1.5 mg as an add‐on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration
por: Pantalone, Kevin M., et al.
Publicado: (2018)

Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled Study
por: Ishii, Hitoshi, et al.
Publicado: (2019)

Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors
por: Zhou, Yan, et al.
Publicado: (2021)

Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials
por: Yamada, Yuichiro, et al.
Publicado: (2021)

Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial
por: Ishii, Hitoshi, et al.
Publicado: (2021)

Necrotizing Pancreatitis Secondary to Dulaglutide Use
por: Bhat, Salman Zahoor, et al.
Publicado: (2021)

Effect of once‐weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD‐2 clinical trial
por: Giorgino, Francesco, et al.
Publicado: (2019)

PSUN270 Magnified Risk of Pancreatitis by GLP-1: A Case of Necrotizing Pancreatitis in a Patient on Dulaglutide with Baseline Elevated Triglycerides
por: Yau, Alice, et al.
Publicado: (2022)

Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics
por: Kolb, Martin, et al.
Publicado: (2023)

Effects of once‐weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials
por: Tuttle, Katherine R., et al.
Publicado: (2016)

Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis
por: Patel, Hiren, et al.
Publicado: (2019)

Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease
por: Lukin, Dana J., et al.
Publicado: (2020)

Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline
por: Pratley, Richard E, et al.
Publicado: (2022)

Glycemic Improvement Using Continuous Glucose Monitoring by Baseline Time in Range: Subgroup Analyses from the DIAMOND Type 1 Diabetes Study
por: Calhoun, Peter, et al.
Publicado: (2021)

Efficacy and Safety of Once Weekly Dulaglutide in East Asian Patients with Type 2 Diabetes: Subgroup Analysis by Potential Influential Factors
por: Ma, Jianhua, et al.
Publicado: (2020)

Dulaglutide (Trulicity)-Induced Acute Pancreatitis: A Case Report
por: Khan, Abu baker, et al.
Publicado: (2023)

Comparison of the glucagon‐like‐peptide‐1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective study
por: Singh, Priyamvada, et al.
Publicado: (2020)

Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open‐label, phase III, non‐inferiority study
por: Araki, E., et al.
Publicado: (2015)

Baseline Description of the Juvenile Localized Scleroderma Subgroup From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry
por: Wu, Eveline Y., et al.
Publicado: (2019)

Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study
por: Tanaka, Kenichi, et al.
Publicado: (2022)

Case Report of Acute Pancreatitis Associated With Combination Treatment of Dulaglutide and Glipizide
por: Babajide, Oyedotun, et al.
Publicado: (2022)

Baseline Glycated Hemoglobin Values Predict the Magnitude of Glycemic Improvement in Patients with Type 1 and Type 2 Diabetes: Subgroup Analyses from the DIAMOND Study Program
por: Billings, Liana K., et al.
Publicado: (2018)

Advances in the treatment of type 2 diabetes: impact of dulaglutide
por: Thompson, Angela M, et al.
Publicado: (2016)

Durability of Glucose-Lowering Effect of the First Administration of Dulaglutide: A Retrospective, Single-Center, Single-Arm Study
por: Matsushita, Maya, et al.
Publicado: (2018)

Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis
por: Yu, Miao, et al.
Publicado: (2020)

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics
por: García-Pérez, Luis-Emilio, et al.
Publicado: (2021)

Comparison of the injection‐site experience of the starting doses with semaglutide and dulaglutide: A randomized, double‐blind trial in healthy subjects
por: Snitker, Søren, et al.
Publicado: (2021)

Efficacy of Dulaglutide Expanded Doses by Baseline A1C Categories: Post Hoc Analysis of AWARD-11
por: Frias, Juan Pablo, et al.
Publicado: (2021)

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes
por: Boye, Kristina S., et al.
Publicado: (2020)

PSUN241 A Case of Dulaglutide-Induced Acute Pancreatitis in a Diabetic Patient – A Case Report
por: Abdelmasih, Randa, et al.
Publicado: (2022)

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials
por: Kashiwagi, Atsunori, et al.
Publicado: (2016)

The renoprotective effect of once‐weekly GLP‐1 receptor agonist dulaglutide on progression of nephropathy in Japanese patients with type 2 diabetes and moderate to severe chronic kidney disease (JDDM67)
por: Tsuchida, Ken‐ichi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_32u48kfoehvkopf0dvrovarqjd